Katie Robinson

The use of biological DMARDs was similar across countries, but in less wealthy countries, more patients with moderate/high disease activity were not receiving biologics.

A personal history rather than a family history of psoriasis is associated with the disease activity and severity of axial joint damage.

One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.

In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.

The survey found 42% of patients with psoriatic disease had never discussed treatment goals with their provider, and less than half of patients with psoriatic arthritis were treated by a rheumatologist.

Patients treated with ixekizumab had higher rates of simultaneous complete skin and nail clearance compared with etanercept, ustekinumab and adalimumab.

Free or total 25(OH)D serum levels were not associated with psoriasis disease severity in this small study of biologic-naïve patients.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.

Meningitis is the most frequent clinical syndrome in SLE patients with CNS infections. C. neoformans, M. tuberculosis and L. monocytogenes are the most common causative pathogens.

The use of antimalarials was associated with a lower prevalence of congestive heart failure in a large Spanish cohort of patients with SLE.

Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.

In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.

In this Q&A, corresponding author, Fiona Watt, MBBS, PhD, FRCP, discusses her study that found the combination of effusion and hemarthrosis at the time of acute knee injury is associated with adverse outcomes at 2 years post-injury.

Patients with autoimmune inflammatory rheumatic diseases had an increased risk of testing positive for SARS-CoV-2 and worse clinical outcomes of COVID-19, including death, although disease-modifying antirheumatic drugs (DMARDs) did not increase the risk of these outcomes.

In patients with psoriatic arthritis (PsA), guselkumab (Tremfya, Janssen Immunology) treatment reduced serum protein levels of acute phase and T-helper cell 17 (Th17) effector cytokines, achieving comparable levels to those in healthy controls.

In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.

For patients with psoriatic arthritis (PsA), multidomain disease was associated with worse measures of disease activity, quality of life, and work productivity.

"Our results suggest that there are likely to be certain treatments that will confer preferential response in psoriatic arthritis (PsA), including tumor necrosis factor (TNF) inhibitors and IL-17 medications, compared to other options," stated Jeffrey Curtis, MD.

Patients with rheumatoid arthritis (RA) have a poorer prognosis after myocardial infarction (MI) than patients without RA, and longer RA disease duration and glucocorticoid use before MI are associated with higher mortality and recurrent MI.

In this systematic review and meta-analysis, investigators aimed to evaluate the clinical safety of total glucosides of paeony (TGP) adjuvant therapy in the treatment of rheumatoid arthritis (RA).

The diagnosis of psoriatic arthritis (PsA) may be delayed by more than 2 years in half of patients, especially those of younger age at symptom onset, or with a higher body mass index (BMI) or enthesitis before diagnosis.

In patients with psoriatic arthritis refractory or intolerant to biologic disease-modifying antirheumatic drugs (DMARDs), upadacitinib (Abbvie; Rinvoq) 15 mg and 30 mg once per day was more effective than placebo over 24 weeks in improving signs and symptoms of psoriatic arthritis.

Investigators determined, “Treatment with TNF inhibitors is not associated with increased risks of solid cancer overall, or eight common cancer types. There were no indications of different crude incidence of solid cancers overall by TNF inhibitor agent.”

Improvement in ASAS20 (Assessment of SpondyloArthritis international Society) was seen in 63% of participants assigned to secukinumab 300 mg and 66% of those assigned to secukinumab 150 mg, versus 31% of the placebo group.

A survey of rheumatologists in the United States found that their prescriptions of medications such as NSAIDs, biologics and steroids during the COVID-19 pandemic is based on regional case burden rather than American College of Rheumatology guidance.

Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.

In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.

In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.